Braveheart Bio closed a $185 million financing to run registration‑enabling studies for a hypertrophic cardiomyopathy (HCM) small‑molecule licensed from Jiangsu Hengrui. Investors include Andreessen Horowitz, Forbion, OrbiMed and others; Biogen’s CEO was named chair of the company’s board. The startup is positioning the asset as a potential best‑in‑class challenger in a crowded cardiometabolic space and will advance global late‑stage trials next year. Management emphasized rapid trial scale and strategic partnerships to accelerate development. Large, single‑asset spinouts backed by major investors reflect continuing appetite for late‑stage clinical opportunity in cardiovascular disease despite a cautious biotech funding climate.